Ajanta Pharma Q2 Review: Stock Rally Limits Upside Despite Robust Performance, Says Systematix
Systematix rate stocks including a list of stocks.
· NDTV Profit
The brokerage incorporates Ajanta Pharma's quarterly performance into its estimates and expect India to remain a key growth driver, supported by sustained outperformance against IPM, while factoring in normalisation in Africa institutional business.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- Brokerage calls from Systematix, with ratings on the stocks named.
- Sectors in the story: Pharma & Healthcare.
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Why is market rallying today? Sensex soars over 950 pts, Nifty tops 23,300. 7 factors driving Rs 4 lakh crore D-Street gains
Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses